Gritstone bio, Inc.
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for tre… Read more
Market Cap & Net Worth: Gritstone bio, Inc. (GRTSQ)
Gritstone bio, Inc. (NASDAQ:GRTSQ) has a market capitalization of $0.92 ($0.92) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #51401 globally and #16125 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gritstone bio, Inc.'s stock price $0.00 by its total outstanding shares 9162 (9.16K).
Gritstone bio, Inc. Market Cap History: None to None
Gritstone bio, Inc.'s market capitalization history from None to None. Data shows growth from $- to $- (0.00% CAGR).
Gritstone bio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gritstone bio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GRTSQ by Market Capitalization
Companies near Gritstone bio, Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Gritstone bio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Gritstone bio, Inc. Historical Marketcap From None to None
Between None and today, Gritstone bio, Inc.'s market cap moved from $- to $ -, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| No historical data available. | ||
End of Day Market Cap According to Different Sources
On Apr 5th, 2025 the market cap of Gritstone bio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $0.92 USD |
| MoneyControl | $0.92 USD |
| MarketWatch | $0.92 USD |
| marketcap.company | $0.92 USD |
| Reuters | $0.92 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.